Ann: AD-214 Phase I extension clinical study - interim results, page-13

Hello fellow 1AD holders, I've been accumulating slowly.

Great value here with an EV of 5mil and 10mil MC.

compared to other companies you're getting a huge pipeline of projects and I really like the internal research team combines with I bodies.

endless factory of IP.

Im quietly confident a deal is coming soon and the company is hoping to get the MC to 100m in the near term based on interviews.

fantastic short term opportunity here and an even better long term opportunity.

you've also already got orphan status which is huge for approvals. And for a market that's quite large for an orphan drug.

going into phase 2 with first and best in class technology.

other comparable companies you're paying more just for car-t here you get that and ibodies for less.

still a fair amount of risk but the talk around partnerships suggests the clinical data should continue to be positive.

exciting times ahead, I'll continue to accumulate.

all imo dyor.